New Alzheimer's drug passes early safety check in small study
NCT ID NCT05804383
First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 21 times
Summary
This early-stage study tested the safety and tolerability of a new drug called BMS-984923 in 51 healthy older adults and people with Alzheimer's disease. Researchers gave increasing doses to see if it caused side effects or lab changes. The goal was not to treat the disease but to gather safety data for future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Spaulding Clinical Research
West Bend, Wisconsin, 53095, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.